Aptar Pharma will host an online scientific webinar focused on the Nasal Drug Delivery Route in the treatment of central nervous system (CNS) diseases. The topic is ‘Nasal Drug Delivery Journey: From Systemic To Nose-To-Brain’.
According to the company, the panel will be composed of our experts, Pierre Carlotti and Gerallt Williams from Aptar Pharma, and Julie Suman from Next Breath. Participants may join this webinar on September 8 (4 PM – Paris time/10 AM New York time). This scientific webinar is complimentary upon registration at: http://bit.ly/1UQoxDi
The webinar will be presented live and will include interactive exchanges with registered participants. The Aptar Pharma webinar will feature discussions on the unmet medical needs and market opportunities for nasal drug delivery to treat CNS diseases. It will also provide details on drug transport into the CNS via the nasal route, focus on nasal drug delivery devices that target CNS-related diseases. Further, it will highlight the new opportunities in areas such as nose-to-brain drug delivery.
Healthcare must adjust to these changing demographics. In addition, the world is facing multiple unmet medical needs. Several changes - new therapeutic options, shorter hospital stays, increased outpatient care and more self-administration of drugs, to name a few, are imperative within a short time frame.
The pharmaceutical and biotech industries are striving to provide affordable solutions to these challenges. This environment provides a wide range of opportunities for the Central Nervous System (CNS) drug market which was $145 billion in 2015 in the future treatment of patients. It will cover areas such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, migraine, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety and bipolar disorders. Now new CNS drug delivery options will benefit patients and enhance overall healthcare.
Aptar Pharma’s product offering dedicated to the CNS within this segment of the Nasal Route is unique, as it allows for the non-invasive delivery of compounds to treat both chronic and acute diseases, via the systemic circulation and/or potentially via the nose-to-brain pathway, by targeting regions of interest in the nasal cavity.
The range of specific drug delivery devices, in particular the Unit-Dose System (UDS) powder, is designed to address this administration route and related therapies, helping our clients meet unmet medical needs and contributing to improved patient adherence and treatment in a challenging environment, stated the company note.